Skip to main content
OpenTrials
Completed

NCT Number: NCT03683212

Early and Comprehensive Care Bundle in Elderly for Acute Heart Failure: a Stepped Wedge Cluster Randomized Trial

This is a prospective multicentre (N=15), stepped-wedge randomized trial that aims to evaluate the benefit of a protocolised comprehensive care bundle for early management of acute heart failure in the ED.

Completed

Looking for future studies?

Notify Me

Key information

Age range

75 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emergency department Hospital Pitié-Salpêtrière

Paris, 75013, France

About this study

Acute heart failure (AHF) is one of the most common diagnoses for elderly patients in the emergency department (ED), with an admission rate higher than 80% and 1-month mortality around 10%. There is scarce evidence of any clinical added value of a specific treatment to improve outcomes, and European guidelines for the management of AHF are based on moderate levels of evidence, due to the lack of randomized controlled trials. Recent reports suggest that the very early administration of full recommended therapy may decrease mortality. However, several studies highlighted that elderly patients often received suboptimal treatment: For example, less than a third of them received nitrates therapy while it is recommended. Furthermore, a recent preliminary study reported that only 50% of them are assessed for precipitating factors - although it has been reported that precipitating factors are independently associated with mortality.

The hypothesis of the Elisabeth Study s is that an early care bundle that comprises early and comprehensive management of symptoms, along with prompt detection and treatment of precipitating factors should improve AHF outcome in elderly patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 75 years and older admitted to the emergency department with a diagnosis of acute heart failure determined by the emergency physician, based on the presence of:
  • at least one of the following symptoms : acute, or worsening of dyspnea, orthopnea
  • one or more of the followings: pulmonary rales, peripheral edema, a chest radiograph or transthoracic echocardiography showing pulmonary vascular congestion signs, increased natriuretic peptides (BNP or NT-pro-BNP).
  • Patients affiliated to French social security ("AME excepted")
  • Written informed consent signed by the patient / the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will been signed by the patient (if need be by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code)

Exclusion criteria

  • Patients are excluded if they have any of the followings:
  • other obvious cause of acute illness (severe sepsis, ST elevation Myocardial infarction)
  • systolic blood pressure less than 100 mmHg
  • severe mitral or aortic stenosis, or severe aortic regurgitation
  • known chronic kidney injury on dialysis
  • shock from any cause
  • Time from ED entrance to inclusion > 6h
  • Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom

Treatment and study plan

Early intensive care bundle

Procedure

The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:

  • Treatment of the congestion: (international guidelines and recommendations)
  • Treatment of precipitating factors
  • NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH < 7.35 in absence of contra indication.
  • Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy.

Primary outcomes

  1. Number of days alive and out of hospital

    Time frame: 30 days

    Number of days alive and out of hospital

Secondary outcomes

  1. To evaluate the effect of AHF management on the 30-day cardiovascular death

    Time frame: 30 days

    cardiovascular death

  2. To evaluate the effect of AHF management on the 30-day all causes death

    Time frame: 30 days

    all causes death

  3. To evaluate the effect of AHF management on the hospital readmission at 30 days

    Time frame: 30 days

    hospital readmission

  4. To evaluate the effect of AHF management on the length of stay in hospital

    Time frame: 30 days

    length of stay in hospital

  5. To evaluate the effect of AHF management on changes of more than 2 fold in creatinine level from randomization to day 30 or to discharge whichever comes first

    Time frame: 30 days

    creatinine level

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: ELISABETH

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 25, 2018
Registry last updated
Jul 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.